CHALLENGESIN SELECTING



KAN RHYTHM CONTROL

Suzanne Murray, AXDEV Group, Matthias Antz, Oldenburg Heart Center, Hein Heidbuchel, Hasselt University, Celine Carrera, European Society of Cardiology, Patrice Lazure, AXDEV Group, Alec Vahanian, Bichat University Hospital, Gerhard Hindricks, University of Leipzig Heart Center

BACKGROUND

- ESC Guidelines Update (2012) on Management of AF
 - Need to gain understanding on how guidelines are implemented in practice
- Canadian Needs Assessment in AF (2010-2011)
 - Used as model to be adapted to the European context / 2015

STUDY OVERVIEW



- Review findings from Canadian Study
- Literature Review
- Consultation with
- Subject Matter Experts
- Ethics (IRB) approval

Use and

Development of evidence based educational programs External dissemination:

Dissemination

Peer-reviewed journal Conference

Qualitative Exploration

- Key Informant Interviews (n:30)
- General Practitioners/
- Neurologists
- Cardiologists Family Physicians

(n:531)

- Online Survey
- Cardiologists
- General Practitioners/ Family Physicians

Quantitative

Validation

Neurologists

Analysis / Interpretation

- Mixed-methods analysis
- Evidence-based identification of gaps, needs, barriers and challenges

STUDY PURPOSE

Identify gaps and challenges faced by cardiologists, neurologists & GPs/FPs in 6 countries in the care of Atrial Fibrillation patients to inform evidence-based continuing education

66 CASE #1

Medical history:

- Hypertension, well-controlled Mitral regurgitation grade 2/4;
- tricuspid regurgitation grade 2/4
- No pulmonary hypertension. LVEF 57%

Current medication:

- Perindopril 4 mg/d
- Bisoprolol 5 mg/d

At consultation:

- First episode of AF since 15 hours **Symptoms:**
- Palpitation. No HF symptoms/signs.

HR:92/min.

- BP: 124/84 mmHg.
- Lab: Hb 13.6 g/dl; creatinine 1.35 mg/dl; CrCl (Cockcroft-Gault) 66 ml/min

Inited Kingdon SAMPLE (n=561)

	7	9	#	4	S		K
PROFESSION	FR	GE	IT	РО	SP	UK	TOTAL
Cardiologists	45	55	62	44	45	43	294
Neurologists	22	22	21	21	24	21	131
GPs/FPs	23	21	22	25	23	22	136
Total	88	100	108	87	91	87	561

Clinical decision-making: rhythm vs. rate control

■ Majority of participants chose Rhythm Control

Variation by country as to when and how to restore sinus rhythm

	Selected Rhythm Control	Cards	81	94	98	93	95	85	92	
		Neuros	86	67	90	80	78	70	78	
		GPs/FPs	70	91	79	71	71	50	72	
	Selected to restore	Cards	53*	75	93	97	90	79	83	
	sinus rhythm within first 24hr	Neuros	56*	100	83	88	83	71	80	
		GPs/FPs	86	65	95	93	93	82	85	
	Selected trial of	Cards	77	27*	74	79	70	62	64	
anti-arrhythmic drug, and then D cardioversion	anti-arrnythmic drug, and then DC	Neuros	83	71	78	94	72	57	77	
	cardioversion	GPs/FPs	86	40*	84	100	73	46*	71	
	* statistically significant difference									

statistically significant difference at the p=0.05 level

Selecting rhythm control strategy

Clinical decision-making:

rhythm vs. rate control

PROFESSION

Cards

Neuros

Cardiologists

Selected Rhythm

Control

"Sometimes picking the right anti-arrhythmic for patient can be a challenge because there are so many different factors that you have to put in, in terms of the impairment of the symptoms or the medical conditions, interaction." - Cardiologist, UK

SUMMARY OF KEY FINDINGS



- Underuse of pathophysiological classification of AF (K, S, A)
- **DIAGNOSIS**

 - TREATMENT
- **MANAGEMENT**
- REFERRAL/
- TEAM
- CONTEXT
- 2A Difficulties in the detection of AF (S, A)
- 3A Uncertainty when making treatment decisions (K, S, A) 4A Issues selecting stroke prevention
- treatment (K, S, A) 4B Underuse of risk assessment tools (K, S, A)
- 4C Difficulties discussing treatment with patients (S)

5A Sub-optimal collaboration between

Sy-System

- specialists and GPs (S, A, Sy) 6A National/regional regulations
- impacting use of NOACs (Sy) K- Knowledge A-Attitudes



DECISION-MAKING PROCESS

PATIENT CONDITION **SCREENING** REFERRAL **PRE-DIAGNOSIS CONFIRM DIAGNOSIS** MANAGEMENT OF PATIENT / MONITORING OF TREATMENT **CONTEXT**

CHALLENGES IN THE CLINICAL

Gap: 3A Uncertainty when making treatment decisions

Causalities: Challenges selecting rhythm

- control & rate control strategies Knowledge, skill & confidence issues selecting patients for AV node ablation
- Challenges remaining current on new therapies & clinical trials

Potential Clinical Implications:

- Trial and error in treatment selection
- Need to adjust treatment strategy frequently
- Patients do not receive AF treatment suited to their profile

CASE #2

Medical history

WOMAN

- Hypertension, dilated cardiomyopathy (ejection fraction 40% for years)
- Current medication
- Enalapril 10 mg/d
- Bisoprolol 2.5 mg/d

Reason for consultation

- Since 8 weeks: irregular HR is displayed when she measures her BP.
- No palpitations. Reduced exercise tolerance.
- 2d ago weakness of left arm & leg which resolved after 6 hours

Work up

- HR: 115/min, BP:135/88 mmHg, Weight: 100kg
- Moderate malleolar oedema.
- CVP elevated; no rales
- Echo: aortic stenosis 2/4 and normal LV-function Lab: Hb 14 g/dl; creatinine 1.3 mg/dl; CrCl (Cockcroft-Gault) 54 ml/min

Diagnosis

Persistent AF and TIA

GPs/FPs * statistically significant difference at the p=0.05 level Selection of Rate Beta-Blockers Calcium Channel Blockers **Control Treatment** Digioxin AV Node Ablation with Pacemaker 80 63% 60 20 4%

Majority of participants selected Rate Control using Beta-Blockers

GPs/FPs responses show greater variability in treatment selection

"The procedures are long and complex. They require the use of specific equipment (...), mapping systems, and trained professionals. The main challenge is treating these patients with the ablation, which is a long, complex and delicate procedure."


- Cardiologist, Italy

GPs/FPs

SELECTING PATIENTS FOR AV NODE ABLATION

All three groups reported skill issues. Neurologists and GPs/FPs also reported knowledge & confidence issues

No statistically significant differences by country



C- Confidence (1-Low to 5-Optimal)

CONCILISION

- Findings corroborate those of the Canadian study
- Variability in the skills and treatment decision preferences of physicians
- Differences between countries may indicate variation in implementation of guidelines and/or in access to treatment options
- Findings call for targeted, locally adapted, specialty-specific, educational interventions to improve and standardise care provided to AF patients



Axdev16-1408_Affiche_V3.indd





ENVIRONMENT